184 related articles for article (PubMed ID: 31804663)
1. Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era.
Calkins KL; Chander G; Joshu CE; Visvanathan K; Fojo AT; Lesko CR; Moore RD; Lau B
JAMA Oncol; 2020 Feb; 6(2):227-235. PubMed ID: 31804663
[TBL] [Abstract][Full Text] [Related]
2. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting.
Geng EH; Hare CB; Kahn JO; Jain V; Van Nunnery T; Christopoulos KA; Deeks SG; Gandhi M; Havlir DV
Clin Infect Dis; 2012 Dec; 55(12):1690-7. PubMed ID: 22955429
[TBL] [Abstract][Full Text] [Related]
3. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.
Yanik EL; Napravnik S; Cole SR; Achenbach CJ; Gopal S; Dittmer DP; Olshan AF; Kitahata MM; Mugavero MJ; Saag M; Moore RD; Mathews WC; Hunt P; Eron JJ
AIDS; 2014 Apr; 28(7):979-87. PubMed ID: 24681415
[TBL] [Abstract][Full Text] [Related]
4. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
[TBL] [Abstract][Full Text] [Related]
5. CD4+ count-guided interruption of antiretroviral treatment.
; El-Sadr WM; Lundgren J; Neaton JD; Gordin F; Abrams D; Arduino RC; Babiker A; Burman W; Clumeck N; Cohen CJ; Cohn D; Cooper D; Darbyshire J; Emery S; Fätkenheuer G; Gazzard B; Grund B; Hoy J; Klingman K; Losso M; Markowitz N; Neuhaus J; Phillips A; Rappoport C
N Engl J Med; 2006 Nov; 355(22):2283-96. PubMed ID: 17135583
[TBL] [Abstract][Full Text] [Related]
6. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
[TBL] [Abstract][Full Text] [Related]
7. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
[TBL] [Abstract][Full Text] [Related]
9. CD4/CD8 Ratio and CD4 Nadir Predict Mortality Following Noncommunicable Disease Diagnosis in Adults Living with HIV.
Castilho JL; Turner M; Shepherd BE; Koethe JR; Furukawa SS; Bofill CE; Raffanti S; Sterling TR
AIDS Res Hum Retroviruses; 2019 Oct; 35(10):960-967. PubMed ID: 31407605
[TBL] [Abstract][Full Text] [Related]
10. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
[TBL] [Abstract][Full Text] [Related]
11. Decline of CD4⁺ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals.
Mussini C; Cossarizza A; Sabin C; Babiker A; De Luca A; Bucher HC; Fisher M; Rezza G; Porter K; Dorrucci M;
AIDS; 2011 May; 25(8):1041-9. PubMed ID: 21412128
[TBL] [Abstract][Full Text] [Related]
12. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.
Okulicz JF; Le TD; Agan BK; Camargo JF; Landrum ML; Wright E; Dolan MJ; Ganesan A; Ferguson TM; Smith DM; Richman DD; Little SJ; Clark RA; He W; Ahuja SK
JAMA Intern Med; 2015 Jan; 175(1):88-99. PubMed ID: 25419650
[TBL] [Abstract][Full Text] [Related]
13. Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators.
King JT; Perkal MF; Rosenthal RA; Gordon AJ; Crystal S; Rodriguez-Barradas MC; Butt AA; Gibert CL; Rimland D; Simberkoff MS; Justice AC
JAMA Surg; 2015 Apr; 150(4):343-51. PubMed ID: 25714794
[TBL] [Abstract][Full Text] [Related]
14. CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data.
Kufa T; Shubber Z; MacLeod W; Takuva S; Carmona S; Bor J; Gorgens M; Pillay Y; Puren A; Eaton JW; Fraser-Hurt N
PLoS One; 2019; 14(5):e0217742. PubMed ID: 31150489
[TBL] [Abstract][Full Text] [Related]
15. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
[TBL] [Abstract][Full Text] [Related]
16. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
[TBL] [Abstract][Full Text] [Related]
17. Association of early HIV viremia with mortality after HIV-associated lymphoma.
Gopal S; Patel MR; Yanik EL; Cole SR; Achenbach CJ; Napravnik S; Burkholder GA; Reid EG; Rodriguez B; Deeks SG; Mayer KH; Moore RD; Kitahata MM; Richards KL; Eron JJ
AIDS; 2013 Sep; 27(15):2365-73. PubMed ID: 23736149
[TBL] [Abstract][Full Text] [Related]
18. Is CD4 monitoring needed among ugandan clients achieving a virologic and immunologic response to treatment?
Reynolds SJ; Sempa JB; Kiragga AN; Newell K; Nakigozi G; Galiwango R; Gray R; Quinn TC; Serwadda D; Chang L
AIDS Patient Care STDS; 2014 Nov; 28(11):575-8. PubMed ID: 25290988
[TBL] [Abstract][Full Text] [Related]
19. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.
Clouse K; Pettifor A; Maskew M; Bassett J; Van Rie A; Gay C; Behets F; Sanne I; Fox MP
AIDS; 2013 Feb; 27(4):645-50. PubMed ID: 23169326
[TBL] [Abstract][Full Text] [Related]
20. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
